Copanlisib治疗复发/难治性惰性淋巴瘤的长期安全性与疗效:CHRONOS-1研究2年随访
CHRONOS-1研究2年随访显示,静脉PI3K抑制剂copanlisib治疗复发/难治性惰性B细胞淋巴瘤的客观缓解率为60.6%,中位缓解持续时间14.1个月,中位无进展生存期12.5个月,中位总生存期42.6个月;长期治疗未观察到治疗中出现的不良事件发生率增加或恶化。
要点
- copanlisib的ORR为60.6%,较主要分析新增7例完全缓解。
- 中位DOR、PFS和OS分别为14.1、12.5和42.6个月。
- 治疗超过1年的患者中,TEAE未见发生率增加或恶化。
核心结论
- 长期随访表明,静脉copanlisib治疗复发/难治性惰性B细胞淋巴瘤可获得持久且增强的缓解,且未出现口服PI3K抑制剂所报道的TEAE恶化证据。
研究设计与样本
- CHRONOS-1研究更新分析,纳入142例组织学确诊的惰性B细胞淋巴瘤患者,既往至少2线治疗后复发或难治,接受静脉copanlisib 60 mg(第1、8、15天,28天周期)。
主要发现
- 主要疗效终点(≥4周期后独立评估的ORR)为60.6%,较主要分析新增7例完全缓解。
- 中位DOR为14.1个月(中位随访16.1个月),中位PFS为12.5个月(中位随访14.0个月),中位OS为42.6个月(中位随访31.5个月)。
- 常见TEAE(所有级别/3级/4级)包括一过性高血糖(50.0%/33.1%/7.0%)、腹泻(35.2%/8.5%/0%)、一过性高血压(29.6%/23.9%/0%)和中性粒细胞减少(28.9%/9.2%/14.8%)。
- 严重AE基本无变化,无新发肺炎(4.2%)、腹泻(2.8%)或5级事件;治疗超过1年的患者中TEAE未见发生率增加或恶化。
临床怎么用
- 对于复发/难治性惰性B细胞淋巴瘤,静脉copanlisib可提供持久的疾病控制,长期治疗需关注高血糖、高血压、腹泻和中性粒细胞减少等TEAE。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Safety profiles of oral PI3K inhibitors have resulted in US FDA black box warnings regarding fatal/serious toxicities. The approved intravenous PI3K inhibitor copanlisib has low incidence of severe toxicities and no black box warnings, but chronic treatment effects were unknown. We provide an update on safety and efficacy of copanlisib with a minimum 2-year follow-up of the CHRONOS-1 study. A total of 142 patients with histologically confirmed indolent B-cell lymphoma who had relapsed after or were refractory to ≥2 prior treatments received intravenous copanlisib 60 mg on days 1, 8, and 15 (28-day cycle). The primary efficacy endpoint was objective response rate (ORR) after ≥4 cycles (independent assessment). The predominant histology was follicular lymphoma (n = 104). The ORR was 60.6% (seven additional complete responses since primary analysis). Secondary endpoints of median duration of response, progression-free survival, and overall survival were 14.1 months (median follow-up, 16.1 months), 12.5 months (median follow-up, 14.0 months), and 42.6 months (median follow-up, 31.5 months), respectively. Median safety follow-up was 6.7 months; 26% of patients received treatment for >1 year. Common treatment-emergent adverse events (TEAEs) (all grade/grade 3/grade 4) were transient hyperglycemia (50.0%/33.1%/7.0%), diarrhea (35.2%/8.5%/0%), transient hypertension (29.6%/23.9%/0%), and neutropenia (28.9%/9.2%/14.8%). Serious AEs were largely unchanged, with no new cases of pneumonitis (4.2%), diarrhea (2.8%), or grade 5 events. Note, TEAEs showed no evidence for increased incidence or worsening following longer exposure in patients treated >1 year. Long-term follow-up of patients with relapsed/refractory indolent B-cell lymphoma treated with intravenous copanlisib demonstrated durable, enhanced responses without evidence of worsening TEAEs, as reported for orally administered PI3K inhibitors.
引用
- Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2020. PMID: 31868245. doi:10.1002/ajh.25711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。